ArticleFrontiers in immunology2026
Targeting KIF20A: a new frontier in cancer treatment revealed by multi-omics analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kinesin family member 20A (KIF20A), a microtubule-dependent motor protein of the Kinesin superfamily, is involved in cell division and organelle transport. Its expression is dysregulated in various cancers and is closely related to tumor metastasis and patient prognosis. However, its specific functions in different tumor types and the potential as an anticancer target have not been fully elucidated, and a systematic pan-cancer analysis is lacking. Methods: This study integrated multiple cancer database resources and systematically analyzed the multi-omics alterations of KIF20A in different cancers using R software, including gene expression, genomic variation, methylation status, biological pathways, and clinical value. In addition, we evaluated the regulatory role and immunotherapy potential of KIF20A in the tumor microenvironment through various bioinformatics algorithms. Finally, we explored the impact of KIF20A on the biological behaviors of Kidney Renal Clear Cell Carcinoma (KIRC) cells through Results: KIF20A is localized in the nucleus and participates in the cell cycle process, serving as a core gene for tumor cell growth. It undergoes copy number alterations in various tumors, and its high expression is closely associated with clinical progression, poor prognosis, and activation of classical oncogenic pathways in multiple cancers. Mechanistically, aberrant epigenetic modifications and mutations in hallmark pathways are significant reasons for the dysregulated expression of KIF20A. Furthermore, the expression of KIF20A correlates with immune cell infiltration and the expression of immune checkpoint molecules, impacting the efficacy of immunotherapy in various cancers. Conclusion: To our knowledge, this is the first study to reveal the role of KIF20A in tumorigenesis and development from a pan-cancer multi-omics perspective, providing solid theoretical and experimental evidence for KIF20A as a potential anti-cancer therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.